CTIX - Cellceutix Corporation (OTCBB)

[Klipper22]

I've been researching Cellceutix pretty heavily lately. Company is solid with a strong management team. Dr. Menon, who heads up the research team is nothing shy of brilliant. I will post more info on them as I learn it. Lower float play with most shares being held by insiders and the float being held relatively tightly by people that are optimistic about Cellceutix's future (according to CRO, Leo Ehrlich). A basic snapshot of Cellceutix:

Cellceutix Pharmaceuticals, Inc. (OTCBB: CTIX), located outside of Boston in Beverly, MA, is an emerging bio-pharmaceutical company in the business of developing small molecule therapies in areas of unmet medical need. Their primary efforts are in cancer and inflammatory disease, but also have another product in the pipeline that is being formulated to treat autism. Cellceutix flagship product, Kevetrin, is being developed to treat cancers that are resistant to standard treatments. Recently, Cellceutix has announced some exciting results in animal models of multi-drug resistant lung cancer.

Their business strategy is well-described by their company slogan “Compounds for Cures.” Cellceutix has kept a “low profile” as they have been developing their products with the ethical philosophy of their products alone will help patients and this will translate into rewards for shareholders. By biotechnology standards, their pipeline of products is moving forward rapidly through an experienced management and development team with years of experience in researching, developing and marketing pharmaceuticals. By “Over The Counter Bulletin Board” standards, their ethics are virtually unparalleled.

To quote the Cellceutix CEO, George Evans:
“Biotech companies have a tendency to talk excitedly about a lot of very complicated science. The excitement is, of course, genuine as the companies see great promise in what they are doing. But how do we understand what it all means? Just like a lot of other companies, we are doing a lot of very complicated experiments and coming up with a lot of dense data and great graphs. And we really like what we see. I think in our case, however, it is easy to explain what it all means. First, it means that we’ve accomplished a lot in a short time. And second it means that our lead compound, Kevetrin, is showing great promise in treating tumors that are otherwise very difficult to treat. This means hope for patients and value for shareholders.”

HISTORY OF CELLCEUTIX CORPORATION
Cellceutix was established in May of 2007 by Chief Executive Officer, George W. Evans and Chief Scientific Officer, Dr. Krishna Menon. Both have extensive backgrounds and years of experience in all aspects of biopharmaceuticals.
Mr. Evans has more than 25 years of experience in the industry with a great portion of that time spent with Pfizer, Inc. where he was in high-level management. He ending his career there as General Counsel for Pfizer’s worldwide prescription drug unit, and a member of the unit’s leadership team. Mr. Evan’s background also includes being a member of the Editorial Advisory Board and the Finance Committee of the Food and Drug Law Institute and a member of the Board of the City Bar Fund. He is a graduate of Williams College and Columbia University’s Law and Business schools.

Dr. Krishna Menon’s experience and accolades are impressive to say the least. Dr. Menon has nearly 40 years experience in drug development for academia and industry. Some of the highlights of Dr. Menon’s career include:

• Chief Government Veterinarian for a major Parish in Jamaica
• Director of Agriculture for the Cayman Islands in the British Caribbean
• Research Scientist under the acclaimed oncologist, Dr. Emil Frei, at the Dana Farber Cancer Research Institute
• Senior Research Scientist, In Vivo Research (Cancer), at Bayer Pharmaceuticals (Miles Laboratories)
• Operating his own veterinary oncology and drug development consultancy practice
• Group Leader, Cancer In Vivo Research and Clinical Development, for Eli Lilly
• Recipient of the President’s Recognition Award by Lily (This is an award not bestowed annually but rather on only special occasions)

The final component of Cellceutix corporate structure is their Chief Financial Officer, Leo Ehrlich. Mr. Ehrlich has been with Cellceutix since June of 2007. A Certified Public Accountant, Mr. Ehrlich also his his BBA from Bernard Baruch College of the City University of New York and sits on the board at StatSure Diagnostic Systems, Inc. as their Chief Financial Officer. Before coming to Cellceutix, Mr. Ehrlich Mr. Ehrlich was the CFO and a director of Nanoviricides, Inc. from June 1, 2005. until May 2007.

SHARE STRUCTURE (approximate, but very close, as of March 28, 2010)
Authorized Shares: 300,000,000
Outstanding Shares: 92,000,000
Float: 40,000,000
Percent held by insiders: 54%

TRANSFER AGENT
Pacific Stock Transfer Co.
4045 South Spencer Street
Suite 403
Las Vegas, NV 89119
Tel: (702) 361-3033
Fax: (702) 433-1979
E-mail: info@pacificstocktransfer.com

CONTACT INFORMATION
Cellceutix Corporation
100 Cumming Center
Suite 151-B
Beverly, MA 01915
Phone: 978-633-3623
Fax: 978-921-6564
Email: info@cellceutix.com
Website: www.cellceutix.com

*stockcharts does not have their chart. I have requested that it be added to their library.

[Klipper22]

Cellceutix Announces Positive Results With Autism Compound KM-391, Showing Significant Improvements on Key Parameters in Animal Studies

Press Release Source: Cellceutix On Monday March 29, 2010, 6:00 am
BEVERLY, MA--(Marketwire - 03/29/10) - Cellceutix Corporation (OTC.BB:CTIX - News), a bio-pharmaceutical company that develops small molecules to treat cancer and inflammatory disease, today announced positive results in an animal study of its recently acquired autism compound, KM-391. In this carefully conducted study, KM-391 was given orally over 90 days to groups of rats at two dosage levels. At each dosage level, KM-391 demonstrated significant improvements in the test animals when compared to both the "no treatment" group and the "active control" (fluoxetine) group on the parameters of brain plasticity, serotonin levels and behavioral function. These parameters were selected as important indicators of the effect needed to successfully treat autism.

"We are extremely excited about the data on KM-391 and the potential for the compound in this area of urgent medical need," said George Evans, CEO of Cellceutix. "Diagnoses of autism are rising dramatically and the disease takes a terrible toll on families. There is a critical need for new treatments for autism and we are pleased to be part of the effort to find them."

"Research on autism has been difficult because there has been no reliable animal model," said Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. "Fortunately, we were able to tap into some cutting edge research to find a promising model for our study."

An audio link discussing this event is at:

cellceutix - Press Release Audio 3-29-2010

For more details about KM-391and the study, please visit the Cellceutix web site at cellceutix - Home.

About Autism Spectrum Disorders:

Autism is a behavior disorder, characterized by an impairment in social communication, social interaction, and social imagination. Those with autism often have a restricted range of interests and display repetitive behaviors and mannerisms, along with altered reactions to the everyday environment.

More information about autism:

- 1% of the population of children in the U.S. ages 3-17 have an autism spectrum disorder. Prevalence is estimated at 1 in 110 births.
- More children will be diagnosed with autism this year than with AIDS, diabetes & cancer combined.
- 1 to 1.5 million Americans live with an autism spectrum disorder. 1% of the adult population of the United Kingdom have an autism spectrum disorder.
- Fastest-growing developmental disability; 10 - 17% annual growth.
- $60 billion estimated annual cost with 60% of costs in adult services. Cost of lifelong care can be reduced by 2/3 with early diagnosis and intervention.
- Autism receives less than 5% of the current U.S. private research funding, and less than 1% of the total NIH budget, even though it is the most prevalent childhood disorder.

More information about autism spectrum disorders is available on the following websites:

National Institute of Child Health and Human Development (NICHD)
- NICHD - The Eunice Kennedy Shriver National Institute of Child Health and Human Development Official Home Page

Autism Society of America - Autism Society of America:

Autism Speaks, Inc. - Autism Speaks, Home Page

About Cellceutix

Cellceutix Corporation is a preclinical cancer and anti-inflammatory drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin™, which it is developing as a treatment for certain cancers, and KM-391, which it is developing for the treatment of autism. More information is available on the Cellceutix web site at cellceutix - Home.

This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix's actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.

The factors that may cause Cellceutix's actual results to differ from its forward-looking statements include: Cellceutix's current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix's ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix's SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.

Kevetrin and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.

Contact:



Contact:
Cellceutix Corp.
Leo Ehrlich
(978) 633-3623
Email Contact

[Klipper22]

The big spread on CTIX is certainly being a pain. It finally chewed through the ask at .48 and it moved to .55, but the bid is remaining at .28. Actually, it just upticked to move the bid to .29. Long term play, but I still would like to see the spread tighten.

[Klipper22]

Cellceutix CEO, George Evans, interviewed on "Stu Taylor on Business" Radio Show. The audio is available at: http://www.cellceutix.com/Stu_Taylor_Mar-30-2010.wma
Go to 30 minutes into the show to hear about the Cellceutix growth and development of Kevetrin, their cancer drug, and KM-391, their drug being developed for autism.

Press Release from today:

Cellceutix CEO Appears on ‘Stu Taylor on Business’: Cancer and Autism Compounds Are Discussed
BEVERLY, MA–(Marketwire – April 12, 2010) – Cellceutix Corporation (OTCBB: CTIX), a bio-pharmaceutical company that develops small molecules to treat cancer, autism and inflammatory disease, today announced that its CEO, George Evans, appeared on the radio program Stu Taylor on Business on Saturday evening. Mr. Evans discussed a range of issues regarding the Cellceutix portfolio of compounds. Kevetrin™, which is being developed to treat drug resistant cancers, and KM-391, which is being developed to treat autism spectrum disorder were prominently featured. Please visit the Cellceutix web site at cellceutix - Home for a link to the program.
“This type of program is a great opportunity for companies like Cellceutix to get the word out about our important research efforts,” said Mr. Evans. “We are going to keep looking for these chances to tell our story.”
In animal studies, Kevetrin has been found to significantly delay tumor growth in multi-drug resistant lung, breast and colon cancer cell lines. On April 20, Cellceutix will be presenting a poster of important new data on Kevetrin at the American Association for Cancer Research (AACR) in Washington, DC. More information about these studies and the AACR presentation is available on the Cellceutix web site at cellceutix - Home.
KM-391, Cellceutix’s novel compound in development for the treatment of autism, was shown to improve several key parameters in an animal model of autism. Given the urgent medical need in this area, the Company is working as rapidly as possible to move KM-391 toward human studies. The pharmaceutical industry is only recently gearing up to develop drugs that address the primary conditions of autism. At Cellceutix we hope to stay ahead of the curve on autism research.
About Cellceutix
Cellceutix Corporation is a preclinical cancer and anti-inflammatory drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, and KM-391, which it is developing for the treatment of autism. More information is available on the Cellceutix web site at cellceutix - Home.
This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix’s actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.
The factors that may cause Cellceutix’s actual results to differ from its forward-looking statements include: Cellceutix’s current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix’s ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix’s SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.
Kevetrin and KM-391 have not been studied in humans at this time. The Company’s positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.

[Klipper22]

Cellceutix Signs Agreements for KevetrinTM Phase 1 Support; Company Continues to Advance Kevetrin Toward Human Studies Targeting Drug Resistant Cancers

BEVERLY, MA--(Marketwire - May 24, 2010) - Cellceutix Corporation (OTCBB: CTIX), a bio-pharmaceutical company that develops small molecules to treat cancer, autism and inflammatory disease, today announced that it has concluded agreements with PharPoint Reasearch for Phase 1 data management and statistical analysis and with Medical Research Consulting Services for Phase 1 clinical monitoring. The terms of the agreements were not disclosed. These agreements provide the basic resources necessary to conduct the Phase 1 study of the Company's cancer compound, Kevetrin.

"We were looking for elite partners that could provide world class service and with PharPoint and Medical Research Consulting Services we have come to terms with two of the best in the industry," said George Evans, CEO of Cellceutix. "These agreements are the next step in our mission to start the Phase 1 study of Kevetrin ASAP."

"We are pleased to have the opportunity to work with Cellceutix and to bring our skills to bear on the Kevetrin Phase 1 study," said Art Holmes, President of PharPoint. Mr. Holmes continued, "From a corporate standpoint, it is exciting to be involved in the start of a promising clinical program, particularly in the field of oncology where there is an urgent need for new therapies." More information about PharPoint is available at PharPoint Research.

Kevetrin is being developed to treat drug resistant cancers. The Company has reported that Kevetrin showed greater tumor growth delay than standard therapies in animal models of resistant lung cancer, resistant breast cancer and resistant colon cancer. In data recently presented at the American Association for Cancer Research (AACR), the efficacy of Kevetrin in a mouse model of drug resistant lung cancer was shown to increase with increasing dose. The data presented at the AACR also show that the administration of a second cycle of therapy with Kevetrin in the same animal model continues to delay tumor growth without the development of resistance. For more information about these results, please visit the Cellceutix web site at cellceutix - Home.

"I am looking forward to working with Cellceutix on the Phase I clinical trial of their novel development product, Kevetrin, for the treatment of solid carcinomas," said Denise T. Resnik, the Owner of Medical Research Consulting Services. "I have had a long-standing consulting relationship with George Evans's prior employer, and I am sure this relationship will be fruitful as well."

About PharPoint Research

PharPoint Research, Inc. is a niche pharmaceutical development service provider specializing in data management and biostatistics. Our staff has worked together for over a decade and includes some of the most talented professionals in the industry. PharPoint understands the importance of responsiveness and timely deliverables with exceptional quality. We pride ourselves on years of experience, superb repeat client rate and the ability to consistently exceed our client's expectations. Founded in 2006, PharPoint is headquartered in Chapel Hill, NC near Research Triangle Park.

About Medical Research Consulting Services
Medical Research Consulting Services was founded by Denise Resnik and has been in continuous operation since 1982. MRCS provides consulting services to pharmaceutical and biotechnology companies, contract research organizations and professional training organizations in the area of new drug development. It also provides independent investment research and objective analysis for publicly traded companies.

About Cellceutix

Cellceutix Corporation is a preclinical cancer, autism and anti-inflammatory drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, and KM-391, which it is developing for the treatment of autism. More information is available on the Cellceutix web site atwww.cellceutix.com.

This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix's actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.

The factors that may cause Cellceutix's actual results to differ from its forward-looking statements include: Cellceutix's current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix's ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix's SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.

Kevetrin and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.

[Klipper22]

Jun 03, 2010 08:35 ET
Cellceutix CFO Discusses Autism Drug, KevetrinTM and Company Progressions With CEOCFO Interviews and News

BEVERLY, MA--(Marketwire - June 3, 2010) - Cellceutix Corporation (OTCBB: CTIX) is pleased to announce that its Chief Financial Officer, Leo Ehrlich, has been featured in an interview with leading online financial publication, CEOCFO Interviews and News. The interview was conducted by CEOCFO Senior Editor Lynn Fosse and highlighted the uniqueness of Cellceutix and the details that make it stand out from all other biotechnology companies in the industry.

In the interview, Mr. Ehrlich discusses the progressions of KM-391, Cellceutix's compound for the treatment of autism, and Kevetrin, their drug being developed as a treatment for drug-resistant cancers. Mr. Ehrlich explained why their autism drug is revolutionary as there is no drug available today for the treatment of autism. Additionally, Mr. Ehrlich also discusses the company's growth strategy as it relates to future potential partnerships, shareholder value and the strength of the Cellceutix management team.

"We are not dealing with just another cancer drug; we have indications that it is effective against drug-resistant cancers, which is a multibillion dollar market," Mr. Ehrlich explained. "Most cancer drugs currently out there are just another variation of existing cancer drugs, whether they be another platinum based drug or another Taxol. We, however, have a completely new and novel compound."

"We are pleased to have been interviewed by CEOCFO. The interview provides us another opportunity to showcase to our shareholders the many milestones we are achieving and the progressions of our business strategy," commented Mr. Ehrlich.

The interview is available at:
http://www.cellceutix.com/CTIX-Cellc...nges-Color.pdf

http://ceocfointerviews.com

About CEOCFO Interviews & News

CEOCFO Interviews & News is a weekly print online publication, marketing engine featuring publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX, OTC: BB, Pink Sheets) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas.

About Cellceutix
Cellceutix Corporation is a preclinical cancer and anti-inflammatory drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin™, which it is developing as a treatment for certain cancers, and KM-391, which it is developing for the treatment of autism. More information is available on the Cellceutix web site at cellceutix - Home.

This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix's actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.

The factors that may cause Cellceutix's actual results to differ from its forward-looking statements include: Cellceutix's current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix's ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix's SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.

Kevetrin and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.

Contact:
Cellceutix Corp.
Leo Ehrlich
CFO
(978) 633-3623

[Klipper22]

Keep an eye on Cellceutix. I've done a lot of dd on them and they have everything that you can want in a developmental biotech. They're moving forward rapidly with 2 completely unique compounds. By that I mean that they are not derivatives of existing drugs, they are completely novel. Major pharmas are already contacting them because of pre-clinical research and Kevetrin is getting closer to human studies (hopefully in Q4). Their other drug is a treatment for the core aspects of autism. There is nothing like it out there now. Since some of the information has gone public, they are being flooded with correspondence from people regarding the development of the compound. With their strong and proven management and research teams, they have a solid track record. They are sliding under the radar, but they won't be forever.

[Klipper22]

Cellceutix moving forward and expediting pre-clinical testing on KM-391, their compound for the treatment of autism. Kevetrin is drawing closer to Phase 1 human trials.

Cellceutix Responds to Public Support by Expediting Autism Studies; Completes Two Required Safety Pharmacology Studies for Its Cancer Compound

Press Release Source: Cellceutix On Monday June 7, 2010, 6:00 am EDT

BEVERLY, MA--(Marketwire - 06/07/10) - Cellceutix Corporation (OTC.BB:CTIX - News) is pleased to announce its acknowledgment of the many emails, phone calls and letters received regarding KM-391, its novel compound for the treatment of autism. Responding to the public's requests, Cellceutix has drawn upon its many resources and expedited scheduling of additional pre-clinical studies of the compound with the results to be released in upcoming weeks.
Cellceutix worked in cooperation with the world-renowned InterEd Faculty of Clinical Research (IFCR) in India to move rapidly in the development of KM-391. The Company's President and Chief Scientific Officer, Dr. Krishna Menon, as Chancellor of IFCR, was able to request expedited scheduling for the testing of KM-391. The prestigious Cochin University of Science & Technology (CUSAT) followed suit and conducted the testing. The research has been completed and the data is presently being analyzed and will soon be ready for release.

"Through a great collaborative effort between our team at Cellceutix with InterEd and Cochin University, we were able to reduce scheduling time from months to weeks," commented George Evans, Chief Executive Officer of Cellceutix. "Our years of experience in the industry have provided us with valuable resources that were very supportive in our efforts to respond to the critical need for new autism treatments."

The Company previously reported that initial testing conducted with KM-391 on a mouse model has provided promising data. In a carefully conducted study, KM-391 was given orally over 90 days to groups of rats at two dosage levels. At each dosage level, KM-391 demonstrated significant improvements in the test animals when compared to both the "no treatment" group and the "active control" (fluoxetine) group on the parameters of brain plasticity, serotonin levels and behavioral function. These parameters were selected as important indicators of the effect needed to successfully treat autism. Being that KM-391 is a novel compound and not merely a derivative of an existing compound, it is in the spotlight within the autism community and the focus of many communications to Cellceutix regarding its development.

Cellceutix Completes Two Required Safety Pharmacology Studies for its Cancer Compound, Kevetrin

Cellceutix Corporation also announces today that it has completed two animal safety pharmacology studies for its cancer compound, Kevetrin™, that are required by the U.S. Food and Drug Administration (FDA) prior to filing an Investigational New Drug (IND) application. These studies involve assessments of the impact of the administration of a compound on the respiratory and central nervous systems of test animals. In the respiratory study, respiratory rate, tidal volume and minute volume were measured. In the central nervous system study, neuropharmacological effects and effects on body temperature were measured. A cardiovascular safety pharmacology study is nearing completion.

"The results of these studies are very encouraging for the further development of Kevetrin," said Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. "The respiratory and central nervous system studies showed no biologically significant changes compared to controls. Since these studies are required by the FDA for an IND filing, their completion is a major forward step for us."

About Cellceutix
Cellceutix Corporation is a preclinical cancer, autism and anti-inflammatory drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, and KM-391, which it is developing for the treatment of autism. More information is available on the Cellceutix web site at cellceutix - Home.

This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix's actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.
The factors that may cause Cellceutix's actual results to differ from its forward-looking statements include: Cellceutix's current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix's ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix's SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.

Kevetrin and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.
Contact:


Contact:
Cellceutix Corp.
Leo Ehrlich
CFO
(978) 633-3623

[Klipper22]

New Autism Drug Research by Cellceutix on Compound KM-391 Results in Significant Behavioral Changes; Chief Scientific Officer Sees Potential for Company to Emerge as Industry Leader as Pharmas Strive for Revolutionary Autism Treatments

Press Release Source: Cellceutix On Monday June 14, 2010, 6:00 am EDT

BEVERLY, MA--(Marketwire - 06/14/10) - Cellceutix Corporation (OTC.BB:CTIX - News) announced today that a new animal study of its compound for autism spectrum disorder, KM-391, once again demonstrated a positive impact on several measures of behavior associated with autism. As announced last week, Cellceutix expedited the research through a collaborative effort with InterEd Faculty of Clinical Research (IFCR) in India and the prestigious Cochin University of Science & Technology (CUSAT).

In the study, test subjects previously injected with a compound to simulate autistic behaviors were injected with an oxytocin antagonist to intensify the symptoms. Test subjects were divided into four groups, oxytocin antagonist only, oxytocin antagonist plus KM-391 (10 mg/kg), placebo alone and placebo plus KM-391 (10 mg/kg). Measurements were taken of autism related behaviors including: repetitive behavior, self-induced injury, sensitivity to touch, positioning correction, group dynamics, and curiosity. The procedure was repeated with the same animals on days 5 and 10. When KM-391 was given along with the oxytocin antagonist, there was a significant reduction in all 6 autism-related behaviors within 1 to 2 hours.

"We are extremely excited about the results from this phase of testing as it coincides with the previous research," said Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. "Having been involved in the research and development of extremely successful compounds in the past, I am very encouraged by the research results that we are achieving with KM-391 and its development potential as a treatment for autism. In our testing, we have simulated specific characteristics of an autistic brain and behavioral symptoms that result from them. KM-391 has been shown to significantly improve both the physical conditions in the brain and behaviors resulting in our animal models. We now have a basis to expect to emerge as a pharma industry leader in autism."

Initial animal model testing on autism conducted with KM-391 by Cellceutix provided exciting results. In a carefully conducted study, KM-391 was given orally over 90 days to groups of rats at two dosage levels. At each dosage level, KM-391 demonstrated significant improvements in the test animals when compared to both the "no treatment" group and the "active control" (fluoxetine) group on the parameters of brain plasticity, serotonin levels and behavioral function. These parameters were selected as important indicators of the effect needed to successfully treat autism.

"With Pfizer and Novartis recently announcing that they have begun pursuing new treatments for core issues of autism, we are excited to be ahead of the curve," said Leo Ehrlich, CFO of Cellceutix. "The latest research has significantly strengthened the previous data and this puts Cellceutix in the forefront of autism research. While we have already been receiving notoriety in the industry, we believe that this is just the beginning of great things to come for Cellceutix and its shareholders."

More information about this new study is available on the Cellceutix web site at cellceutix - Home.

About Autism Spectrum Disorders:

Autism is a behavior disorder, characterized by an impairment in social communication, social interaction, and social imagination. Those with autism often have a restricted range of interests and display repetitive behaviors and mannerisms, along with altered reactions to the everyday environment.

More information about autism:

* 1 percent of the population of children in the U.S. ages 3-17 have an autism spectrum disorder. Prevalence is estimated at 1 in 110 births.
* More children will be diagnosed with autism this year than with AIDS, diabetes & cancer combined.
* 1 to 1.5 million Americans live with an autism spectrum disorder. 1 percent of the adult population of the United Kingdom have an autism spectrum disorder.
* Fastest-growing developmental disability; 10 - 17 % annual growth.
* $60 billion estimated annual cost with 60% of costs in adult services. Cost of lifelong care can be reduced by 2/3 with early diagnosis and intervention.
* Autism receives less than 5% of the current US private research funding, and less than 1% of the total NIH budget, even though it is the most prevalent childhood disorder.

More information about autism spectrum disorders is available on the following websites:

National Institute of Child Health and Human Development (NICHD) -- NICHD - The Eunice Kennedy Shriver National Institute of Child Health and Human Development Official Home Page

Autism Society of America -- Autism Society of America:

Autism Speaks, Inc. -- Autism Speaks, Home Page

About Cellceutix
Cellceutix Corporation is a preclinical cancer, autism and anti-inflammatory drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin™, which it is developing as a treatment for drug-resistant cancers, and KM-391, which it is developing for the treatment of autism. More information is available on the Cellceutix web site at cellceutix - Home.

This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix's actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.

The factors that may cause Cellceutix's actual results to differ from its forward-looking statements include: Cellceutix's current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix's ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix's SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.

Kevetrin and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.
Contact:



Contact:
Cellceutix Corp.
Leo Ehrlich
CFO
(978) 633-3623

[Klipper22]

I meant to post this when it was released on Monday. Hopefully Kevetrin is in human trials by the end of the year. There's a good chance that it will happen as the IND takes about 3 months to prepare, submit and have approved.

Kevetrin Demonstrates Significant Results in the Treatment of Multi-Drug Resistant Cancer Cells

BEVERLY, MA--(Marketwire - June 21, 2010) - Cellceutix Corporation (OTCBB: CTIX) is pleased to announce that they have concluded more pre-clinical cell studies for Kevetrin, their flagship compound for the treatment of multi-drug resistant strains of lung, breast and colon cancers. The research was conducted on drug resistant non-small cell lung carcinoma cells by the Cellceutix research team at a world-renown cancer hospital in Boston.

The studies were focused on the methods of action with Kevetrin pertaining to the cell life cycle process. Efficient elimination of carcinoma cells requires identifying multi-pathways to treat the affected cells. This research had the purpose of identifying another pathway that Kevetrin may be effective against multi-drug resistant cancer cells. The data compiled from the research showed that Kevetrin had a 78% effective rate of G2/M arrest. The data also showed that cells treated with Kevetrin also demonstrated a 66% increase in apoptosis, defined as a form of cell death, as compared to non-treated cells.

"The G2/M portion of a cancer cell's cycle is critical as it the stage before a cell enters mitosis, the time when the cell divides into 2 identical nuclei. Kevetrin is proving once again to slow or stop the growth of carcinoma cells," stated Cellceutix Chief Scientific Officer Dr. Krishna Menon. "The increased apoptosis is very significant because it shows that the cancer cells are being destroyed without damaging any of the healthy cells around it."

George Evans, CEO of Cellceutix, commented, "This data provides important insight into how Kevetrin is working to attack resistant cancer cells and significant because when dealing with drug-resistant cancers it is imperative to find multiple pathways to destroy the cells." Mr. Evans continued, "We are very excited about the potential Kevetrin is presenting to the value of our company as all pre-clinical data has been extremely promising."

About Cellceutix
Cellceutix Corporation is a preclinical cancer, autism and anti-inflammatory drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin™, which it is developing as a treatment for drug-resistant cancers, and KM-391, which it is developing for the treatment of autism. More information is available on the Cellceutix web site at cellceutix - Home.

This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix's actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.

The factors that may cause Cellceutix's actual results to differ from its forward-looking statements include: Cellceutix's current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix's ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix's SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.

Kevetrin and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.